Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

Use of CXCL9 as a Biomarker of Acthar Efficacy

Phase 4

Recruiting

Conditions: Sarcoidosis

Interventions: Drug: Acthar gel

First Posted Date: 2015-08-14

Last Posted Date: 2023-05-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 14

Registration Number: NCT02523092

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

Phase 1

Terminated

Conditions: End Stage Renal Disease

Interventions: Drug: Acthar Gel

First Posted Date: 2015-07-01

Last Posted Date: 2017-02-10

Lead Sponsor: Youngstown State University

Target Recruit Count: 9

Registration Number: NCT02486744

Locations: 🇺🇸
Center for Dialysis Care 3695 Stutz Drive, Canfield, Ohio, United States

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

Not Applicable

Conditions: Rheumatoid Arthritis

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2015-05-05

Last Posted Date: 2015-05-05

Lead Sponsor: Ronald J. Rapoport, MD

Target Recruit Count: 10

Registration Number: NCT02434757

Locations: 🇺🇸
Phase III Clinical Research, Fall River, Massachusetts, United States

Acthar for Treatment of Post-transplant FSGS

Phase 4

Withdrawn

Conditions: FSGS
Renal Transplantation
Kidney Transplantation

Interventions: Drug: Acthar

First Posted Date: 2015-03-26

Last Posted Date: 2021-08-30

Lead Sponsor: University of North Carolina, Chapel Hill

Registration Number: NCT02399462

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Acthar on Proteinuria in IgA Nephropathy Patients

Phase 4

Withdrawn

Conditions: Proteinuria
IgA Nephropathy

Interventions: Drug: Acthar 80 unit injection

First Posted Date: 2015-03-06

Last Posted Date: 2017-04-05

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT02382523

Locations: 🇺🇸
Harris Health System Smith Clinic or Ben Taub Hospital, Houston, Texas, United States

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

Phase 2

Conditions: Cutaneous Sarcoidosis
Sarcoidosis

Interventions: Drug: ACTHAR Gel 80 units twice weekly.
Drug: ACTHAR Gel 40 units twice weekly

First Posted Date: 2015-01-28

Last Posted Date: 2015-01-28

Lead Sponsor: Albany Medical College

Target Recruit Count: 10

Registration Number: NCT02348905

Locations: 🇺🇸
Albany Medical College, Albany, New York, United States

ACTH for Fatigue in Multiple Sclerosis Patients

Phase 3

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: ACTH
Drug: Placebo

First Posted Date: 2014-12-12

Last Posted Date: 2019-09-09

Lead Sponsor: Providence Health & Services

Target Recruit Count: 8

Registration Number: NCT02315872

Locations: 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸
Providence Medical Group - Medford Neurology, Medford, Oregon, United States
🇺🇸
Swedish Medical Center, Seattle, Washington, United States

and more 2 locations

CNS Sarcoidosis and Acthar Gel

Phase 4

Completed

Conditions: CNS Sarcoidosis

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2014-11-24

Last Posted Date: 2021-04-09

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 4

Registration Number: NCT02298491

Locations: 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States

Effects of Acthar on Recovery From Cognitive Relapses in MS

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Adrenocorticotropic Hormone

First Posted Date: 2014-11-14

Last Posted Date: 2020-04-06

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 64

Registration Number: NCT02290444

Locations: 🇺🇸
University at Buffalo-State University of New York, Department of Neurology, Buffalo General Hospital, Buffalo, New York, United States

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Phase 3

Completed

Conditions: Progressive IgA Nephropathy
Proteinuria

Interventions: Drug: ACTH (Acthar) Gel

First Posted Date: 2014-11-05

Last Posted Date: 2019-06-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT02282930

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy